These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Vasodilators in pulmonary hypertension. Peacock A Thorax; 1993 Dec; 48(12):1196-9. PubMed ID: 8303622 [No Abstract] [Full Text] [Related]
44. The treatment of chronic pulmonary hypertension by vasodilators: hope and hesitation. Jezek V Eur Heart J; 1988 Sep; 9 Suppl J():1-6. PubMed ID: 3053178 [TBL] [Abstract][Full Text] [Related]
45. Rationale for the judicious use of placebos in PAH trials. White RJ; Hiremath J J Heart Lung Transplant; 2010 Jul; 29(7):826-7. PubMed ID: 20471863 [No Abstract] [Full Text] [Related]
46. [Treatment of primary pulmonary hypertension with vasodilator drugs]. Rigau D; Agustí A Med Clin (Barc); 2003 Feb; 120(5):194-6. PubMed ID: 12605828 [No Abstract] [Full Text] [Related]
47. Pulmonary Hypertension: Overview and Case Study. Powell B; Leeper B AACN Adv Crit Care; 2020 Mar; 31(1):57-66. PubMed ID: 32168516 [TBL] [Abstract][Full Text] [Related]
48. Pulmonary hypertension, right ventricular failure, and vasodilator therapy. Making pathophysiologic sense. Davila F Chest; 1986 Sep; 90(3):467-8. PubMed ID: 3743174 [No Abstract] [Full Text] [Related]
49. Vasodilator treatment of primary pulmonary hypertension. Cotter L Adv Exp Med Biol; 1984; 164():359-68. PubMed ID: 6695579 [No Abstract] [Full Text] [Related]
50. Pulmonary vasodilators in postoperative pulmonary hypertension. Kashani IA; Swensson RE Am Heart J; 1983 Oct; 106(4 Pt 1):778-9. PubMed ID: 6613826 [No Abstract] [Full Text] [Related]
52. Long-term clinical trials in pulmonary hypertension. Long overdue. Theodore J; Burke CM Chest; 1986 Jan; 89(1):4-5. PubMed ID: 3510108 [No Abstract] [Full Text] [Related]
53. Papaverine, a vasodilator with antiviral activity. Koch HJ; Raschka C Swiss Med Wkly; 2002 Feb; 132(7-8):105; author reply 105. PubMed ID: 11971205 [No Abstract] [Full Text] [Related]
54. [Vasotropic therapy and artificial respiration for pulmonary hypertension]. Grimminger F; Olschewski H; Seeger W Internist (Berl); 1999 Jul; 40(7):747-55. PubMed ID: 10429917 [No Abstract] [Full Text] [Related]
55. Different vasoactive mechanisms of various pulmonary vasodilators. Lee TS Chest; 1994 Jun; 105(6):1920-1. PubMed ID: 8205926 [No Abstract] [Full Text] [Related]
56. Current trends in research and clinical trials of drugs for chronic pulmonary hypertension. Morpurgo M; Jezek V Eur Heart J; 1988 Sep; 9 Suppl J():39-43. PubMed ID: 3053184 [No Abstract] [Full Text] [Related]
57. Variable Monitoring of Veterans with Group 3 Pulmonary Hypertension Treated with Off-Label Pulmonary Vasodilator Therapy. Johnson SW; Gillmeyer KR; Bolton RE; McCullough MB; Qian SX; Maron BA; Klings ES; Wiener RS Ann Am Thorac Soc; 2022 Jul; 19(7):1236-1239. PubMed ID: 35312466 [No Abstract] [Full Text] [Related]
58. Pediatric and adult patients with pulmonary hypertension and a challenging case. Erol Ç Anatol J Cardiol; 2018 Jul; 20(1):1. PubMed ID: 29952371 [No Abstract] [Full Text] [Related]
59. The Yin and Yang of endothelium-derived vasodilator factors. Kadlec AO; Gutterman DD Am J Physiol Heart Circ Physiol; 2018 May; 314(5):H892-H894. PubMed ID: 29351003 [No Abstract] [Full Text] [Related]
60. [Remarks on the definition of the perinecrotic zone]. Dettli L Vasa; 1973; 2(4):423-5. PubMed ID: 4760366 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]